Literature DB >> 21336119

Human serum albumin improves endothelial dysfunction and survival during experimental endotoxemia: concentration-dependent properties.

Hélène Kremer1, Céline Baron-Menguy, Angela Tesse, Yves Gallois, Alain Mercat, Daniel Henrion, Ramaroson Andriantsitohaina, Pierre Asfar, Ferhat Meziani.   

Abstract

OBJECTIVES: The mechanisms by which human serum albumin might protect against sepsis-induced organ dysfunction and improve survival are not elucidated. The present study was designed to assess the effects of two concentrations of human serum albumin on endotoxin-induced mortality as well as on endothelial and organ dysfunctions in both mouse and cell models.
DESIGN: Prospective, randomized, controlled experimental study.
SETTING: University research laboratories.
SUBJECTS: Swiss mice (n = 10-15/group) were injected with either lipopolysaccharide or vehicle. Four and 12 hrs later, mice were infused or not with human serum albumin HSA (4% or 20%, 10 mL/kg) or normal saline (0.9% NaCl, 30 mL/kg). Human uterine vein endothelial cells were exposed to both lipopolysaccharide and tumor necrosis factor-α during 8 hrs in the presence or absence of human serum albumin (4% or 20%).
MEASUREMENTS AND MAIN RESULTS: Mice survival, reactivity of mesenteric arteries, and Western blot protein analysis were assessed. Circulating endothelin-1, gluthatione, gluthatione disulfide, and creatinine plasma levels were measured. Nitric oxide production, oxidative, and nitrosative stresses were also measured in situ in endothelial cells. Human serum albumin 4%, but not human serum albumin 20% or normal saline solution, improved survival time of endotoxemic mice. Furthermore, human serum albumin 4% activated endothelial nitric oxide synthase and restored lipopolysaccharide-impaired flow-dependent endothelial dilation in mesenteric arteries. This was associated with a downregulation of nuclear factor κB and an upregulation of nuclear respiratory factor-2 and heme oxygenase-1. Human serum albumin 4% reduced lipopolysaccharide-induced renal dysfunction, enhanced endothelin-1 production and glutathione plasmatic levels, whereas human serum albumin 20% increased gluthatione disulfide. Furthermore, human serum albumin 4% but not 20% blunted lipopolysaccharide-tumor necrosis factor-α-induced oxidative and nitrosative stresses in endothelial cells and increased their gluthatione levels.
CONCLUSIONS: The present data confirm a protective effect of 4% human serum albumin treatment both on mice survival and endothelial dysfunction by inhibiting inflammatory and oxidative stress pathways induced by endotoxins. Conversely, higher concentrations of human serum albumin were detrimental suggesting a dose-dependent effect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21336119     DOI: 10.1097/CCM.0b013e318211ff6e

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  16 in total

Review 1.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Human albumin solution for patients with cirrhosis and acute on chronic liver failure: Beyond simple volume expansion.

Authors:  Christopher Valerio; Eleni Theocharidou; Andrew Davenport; Banwari Agarwal
Journal:  World J Hepatol       Date:  2016-03-08

3.  Lower Plasma Albumin, Higher White Blood Cell Count and High-Sensitivity C-Reactive Protein are Associated with Femoral Artery Intima-Media Thickness Among Newly Diagnosed Patients with Type 2 Diabetes Mellitus.

Authors:  Nga Phi Thi Nguyen; Thuc Luong Cong; Binh Thanh Vu; Tuan Dinh Le; Thi Thanh Hoa Tran; Binh Nhu Do; Son Tien Nguyen; Lan Ho Thi Nguyen; Manh Van Ngo; Hoa Trung Dinh; Hoang Duong Huy; Nghia Xuan Vu; Kien Nguyen Trung; Duong Ngoc Vu; Nghia The Pham
Journal:  Int J Gen Med       Date:  2022-03-08

4.  Specific antioxidant properties of human serum albumin.

Authors:  Myriam Taverna; Anne-Lise Marie; Jean-Paul Mira; Bertrand Guidet
Journal:  Ann Intensive Care       Date:  2013-02-15       Impact factor: 6.925

Review 5.  Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease.

Authors:  Manuel Tufoni; Maurizio Baldassarre; Giacomo Zaccherini; Agnese Antognoli; Paolo Caraceni
Journal:  Curr Hepatol Rep       Date:  2020-07-01

Review 6.  Role of albumin in the preservation of endothelial glycocalyx integrity and the microcirculation: a review.

Authors:  Cesar Aldecoa; Juan V Llau; Xavier Nuvials; Antonio Artigas
Journal:  Ann Intensive Care       Date:  2020-06-22       Impact factor: 6.925

7.  Acute kidney injury in postoperative shock: is hyperoncotic albumin administration an unrecognized resuscitation risk factor?

Authors:  Chiedozie I Udeh; Jing You; Matthew R Wanek; Jarrod Dalton; Belinda L Udeh; Sevag Demirjian; Nadeem Rahman; J Steven Hata
Journal:  Perioper Med (Lond)       Date:  2018-12-14

8.  Relationship Between Serum Albumin Levels and Infections in Newborn Late Preterm Infants.

Authors:  Chunyan Yang; Zhaoguo Liu; Min Tian; Ping Xu; Baoyun Li; Qiaozhi Yang; Yujun Yang
Journal:  Med Sci Monit       Date:  2016-01-09

9.  Effects of the Infusion of 4% or 20% Human Serum Albumin on the Skeletal Muscle Microcirculation in Endotoxemic Rats.

Authors:  Elisa Damiani; Can Ince; Fiorenza Orlando; Elisa Pierpaoli; Oscar Cirioni; Andrea Giacometti; Federico Mocchegiani; Paolo Pelaia; Mauro Provinciali; Abele Donati
Journal:  PLoS One       Date:  2016-03-04       Impact factor: 3.240

10.  Effect of albumin administration on outcomes in hypoalbuminemic patients hospitalized with community-acquired pneumonia (ALBUCAP): a prospective, randomized, phase III clinical controlled trial-a trial protocol.

Authors:  Alexander Rombauts; Gabriela Abelenda-Alonso; Antonella Francesca Simonetti; Guillermo Verdejo; Yolanda Meije; Lucia Ortega; Mercedes Clemente; Jordi Niubó; Yolanda Ruiz; Carlota Gudiol; Cristian Tebé; Sebastian Videla; Jordi Carratalà
Journal:  Trials       Date:  2020-08-20       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.